Orexo develops improved specialty pharmaceuticals and treatments for new areas of use – at a lower cost, in a shorter period of time and at a lower risk – by combining known substances with patented proprietary technologies.
Zubsolv® is a product for the maintenance treatment of opioid dependence. On July 3, 2013, the product was approved by the U.S. Food and Drug Administration, FDA and on September 16, 2013, the product was launched on the US market.
Abstral® is a product that provides rapid relief of breakthrough pain in cancer patients. In March 2013, Orexo sold the rights to Abstral in the United States to Galena Biopharma, Inc. Orexo’s Japanese partner Kyowa Hakko Kirin Co., Ltd. holds the rights for Abstral in Japan. In September 2013, Abstral was approved in Japan. ProStrakan Group plc acquired the product rights in the EU and the rest of the world.
Edluar™ is a product for the treatment of short-term insomnia. The specialty pharma company Meda has a global license for Edluar.
Orexo also markets Diabact® UBT, Heliprobe® System and IRIS® through its subsidiary Kibion. These are used in the diagnosis of Helicobacter pylori, the bacterium that causes gastric ulcers.
The OX51 program for the treatment of acute episodes of intense pain is under development.
The OX27 program for a new treatment of breakthrough pain in cancer patients is at present dormant.
In August 2014, Orexo's partner Boehringer Ingelheim decided to return the OX-MPI project to Orexo. The project aims to develop products based on specific inhibition of prostaglandin E2 (PGE2) in different disease conditions. Boehringer Ingelheim has since 2005 been responsible for all research and development within the OX-MPI project.